NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 16 February 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair Topics 1 & 3) Present for all items
2. Dr Stephen Smith (Chair Topic 2) Present for all items
3. Martin Bradley Items 1 to 4.2.2
4. Dr Matthew Bradley Items 1 to 5.2.2
5. Professor Rachel Elliott Present for all items
6. Professor Chris Parker Items 1 to 4.2.2
7. Dr Robert Hodgson Items 5 to 6.2.2
8. Dr Bernard Khoo Present for all items
9. Dr Ivan Koychev Present for all items
10. Dr Guy Makin Present for all items
11. Dr Philip Mallender Present for all items
12. Professor David Meads Present for all items
13. Giles Monnickendam Present for all items
14. Dr Nathan Moore Present for all items
15. Dr Malcolm Oswald Present for all items
16. Dr Rebecca Payne Present for all items
17. Carole Pitkeathley Present for all items
18. Dr Raju Reddy Present for all items
19. Professor John Watkins Present for all items

NICE staff (key players) present

Linda Landells, Associate Director Present for all items

Kate Moore, Project Manager Present for all items

Lizzie Walker, Heath Technology Assessment Adviser Items 1 to 4.2.2

Caron Jones, Heath Technology Assessment Adviser Items 5 to 5.2.2

Fatima Chunara, Heath Technology Assessment Adviser Items 6 to 6.2.2

Samuel Slayen, Heath Technology Assessment Analyst Items 1 to 4.2.2

Emily Leckenby, Heath Technology Assessment Analyst Items 5 to 5.2.2

Owen Swales, Heath Technology Assessment Analyst Items 6 to 6.2.2

Maroulla Whiteley, Business Analyst, Resource Impact Present for all items

Jen Hacking, Senior Medical Editor Items 1 to 4.2.2

Korin Knight, Senior Medical Editor Items 1 to 4.2.2

Ruth Melville, Senior Medical Editor Items 6 to 6.2.2

Emma Gordon, Coordinator, Corporate Office Items 1 to 4.1.3 & 6 to 6.1.3

Staff member, Coordinator, Committee Operations Present for all items

Mohammed Towhasir, Administrator, Technology Appraisals Items 1 to 4.2.2 & 6 to 6.2.2

Liam Murray, Administrator, Committee Operations Items 5 to 5.2.2

NICE staff (observers) present

Rachel Ramsden, Heath Technology Assessment Analyst Items 1 to 4.2.2

Sarah Wilkes, Technical Analyst, Commercial Liaison Items 1 to 4.2.2

Abitha Senthinathan, Heath Technology Assessment Analyst Items 1 to 4.2.2

Thomas Palmer, Technical Analyst, Interventional Procedures Items 1 to 4.2.2

Emily Eaton-Turner, Technical Adviser, Commercial Liaison Items 5 to 6.2.2

External assessment group representatives present

Mark Corbett, NHS Centre for Reviews and Dissemination and Centre for Health Economics -York, Items 1 to 4.1.3

Matthew Walton, NHS Centre for Reviews and Dissemination and Centre for Health Economics -York, Items 1 to 4.1.3

Paul Tappenden, School of Health and Related Research (ScHARR), Items 5 to 5.1.3

Simone Critchlow, Peninsula Technology Assessment Group, University of Exeter (PenTAG), Items 6 to 6.1.3

G.J. Melendez-Torres, Peninsula Technology Assessment Group, University of Exeter (PenTAG), Items 6 to 6.1.3

Clinical & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 1 to 5.2.2

Dr Alistair Greystoke, Senior Lecturer in Medical Oncology, clinical expert nominated by Novartis, Items 1 to 4.1.3

Dr Sanjeev Patel, Innovative Medicines Fund Clinical lead, NHS England, Items 6 to 6.2.2

## Minutes

### Introduction to the meeting

* 1. The chair Dr Megan John welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr Andrew Hitchings, Dr Athanasios Saratzis, Professor Sofia Dias, Christopher Herring and Dr Soo Fon Lim.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 19 January 2023.

### Appraisal of dabrafenib with trametinib for treating advanced BRAF V600 mutation-positive non-small-cell lung cancer [ID3851]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis pharmaceuticals.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor Chris Parker declared non-financial professional interests is he is the co-chief investigator of a trial of PSMA lutetium for prostate cancer sponsored by the MRC but funded by Novartis. It was agreed that his declaration would not prevent Professor Parker from participating in discussions on this appraisal
* Committee member Professor David Meads declared financial interests as the University of Leeds has received funding from BMS for research in an unrelated area. It was agreed that his declaration would not prevent Professor Meads from participating in discussions on this appraisal.
* Committee members Dr Robert Hodgson & Professor Sofia Dias were part of the EAG for this appraisal as a direct conflict neither participated discussions on this appraisal.
* Nominated clinical expert Dr Alastair Greystoke declared financial interests as he has received consultancy and speakers’ fees from Novartis in relation to the management of NSCLC; and not related to the subject of this appraisal It was agreed that his declaration would not prevent Dr Greystoke from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Carole Pitkeathley, Martin Bradley and Dr Phillip Mallander.
  1. Part 2 – Closed session (company representatives, clinical expert, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10913>

### Appraisal of ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more therapies [ID3805]

* 1. Part 1 – Open session
     1. The chair Dr Stephen Smith welcomed the invited NHS England expert, external assessment group representatives, members of the public and company representatives from Deciphera Pharmaceuticals.
     2. The chair asked all committee members and expert, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* No interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 - Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10671>

### Appraisal of voclosporin with immunosuppressive therapies for treating lupus nephritis [ID3962]

* 1. Part 1 – Open session
     1. The chair Dr Megan John welcomed the invited NHS England expert, external assessment group representatives, members of the public and company representatives from Otsuka Pharmaceuticals.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
  + Committee member Professor David Meads declared that he has conducted consultancy work for Otsuka in an unrelated area. The funding went to the University of Leeds and personally to him. It was agreed his declaration would not prevent Professor Meads from participating in discussions on this appraisal.
  + Committee member Dr Matt Bradley has declared that he is employed by GSK the manufacturer of belimumab. Although this medicine hasn't been reviewed by NICE, it is licensed for use in Lupus Nephritis. It was agreed that as a direct conflict Dr Bradley would not participate in discussions on this appraisal.
  + No further interests were declared for this appraisal.
    1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10878>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 16 March and will start promptly at 09:30.